Comparative Pharmacology
Head-to-head clinical analysis: ELFABRIO versus VIMIZIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELFABRIO versus VIMIZIM.
ELFABRIO vs VIMIZIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human α-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal α-galactosyl groups, thereby reducing accumulation in tissues.
VIMIZIM (elosulfase alfa) is a recombinant human N-acetylgalactosamine-6-sulfatase that hydrolyzes the sulfate ester bond at position 6 of N-acetylgalactosamine in chondroitin sulfate and keratan sulfate, thereby reducing glycosaminoglycan (GAG) accumulation in patients with Morquio A syndrome (mucopolysaccharidosis IVA).
1 mg/kg intravenously over 2 hours every 2 weeks.
2 mg/kg administered intravenously once weekly over approximately 4 hours. Pretreat with antihistamines and antipyretics 30-60 minutes prior to infusion.
None Documented
None Documented
Terminal elimination half-life approximately 0.5–1 hour; short half-life necessitates twice-weekly intravenous dosing.
Terminal elimination half-life approximately 9.8 days (range 7.7–13.8 days) in patients with mucopolysaccharidosis VI (MPS VI). Long half-life supports weekly intravenous dosing.
Primarily eliminated via renal excretion as intact protein; minimal biliary/fecal elimination (<1%).
Primarily renal. No specific data on biliary or fecal elimination; as a recombinant enzyme, likely catabolized to peptides and amino acids, with renal excretion of metabolites.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy